Corbion announced on October 2, 2026 that Olivier Rigaud, Chief Executive Officer, informed the supervisory board that he will not seek a third term when his current mandate expires at the annual general meeting of shareholders on May 12, 2027.
After eight years at the helm of the company, he believes that the end of his current term constitutes the right moment to hand over the leadership of the enterprise. He will remain in office and continue to lead the company until the general meeting on May 12, 2027, focusing on improving performance, strengthening execution and advancing strategic priorities.
Xander Wessels Proposed to the Supervisory Board
Free · Every morning
Technical market signals, before the opening bell.
Bullish and bearish momentum, analyst changes, stocks to watch — automatically computed from Euronext data.
✓ Before 9 AM every morning✓ Euronext data✓ AI-powered analysis
You're in — subscription confirmed!
Your first edition is on its way. Check your spam folder and add us to your contacts.
An error occurred.
Indicative data. No investment advice. Unsubscribe at any time.
Gratuit · chaque matin
Ne ratez plus rien sur vos actions
La tendance derrière les cours. L'essentiel des valeurs Euronext en quelques minutes.
📈les valeurs en mouvement, sur la durée
🎯les objectifs d'analystes qui évoluent
📰les actualités qui font bouger les cours
tendance · 6 séances
✓ C'est fait, vous êtes inscrit !
Votre première édition arrive bientôt. Pensez à vérifier vos spams.
Une erreur est survenue.
CAC 40 · SBF 120 · données indicatives · aucun conseil en investissement · désinscription à tout moment.
The supervisory board has launched a succession process to identify the next Chief Executive Officer of Corbion.
Furthermore, the board intends to propose the appointment of Alexander (Xander) Wessels as a member of the supervisory board at an extraordinary general meeting. A Dutch national, he has held several senior positions, including Chief Executive Officer of Caldic, Chief Executive Officer of Archroma, and President and Chief Executive Officer of DSM Pharmaceutical Products. He currently chairs the supervisory board of NRG Pallas and chairs Enza Zaden, and is a member of the board of directors of Archroma.
SectorAgroalimentaire et boissons›Industrie alimentaire
Free · every morning · before 9am
Never miss a move on your stocks
The trend behind the prices · Euronext
✓ You're in! Check your spam folder.
An error occurred.
Context
Period
Period: S1 2026
Key reported figures
Revenue: 631,1 millions d'euros
Quarterly revenue: 631,1 millions d'euros
EBITDA: 85 millions d'euros
EBITDA margin: 14,1 %
Net income: 29,8 millions d'euros
Free cash flow: -4 millions d'euros
481,6 millions d'euros
Guidance from the release
we are refining our 2026 guidance to an Adjusted EBITDA margin of above 16% (previously ~17%)
Outlook / guidance
Management commentary: Organic sales growth
The information presented in this article is provided for informational purposes only and does not constitute an investment recommendation, an incentive to buy or sell a financial asset, or investment advice. Readers are invited to conduct their own research before making any decision.
Investments in the stock market involve risks, including the risk of capital loss. Past performance of an asset or market is no guarantee of future results. Any investment decision should be made taking into account your personal financial situation, objectives and risk tolerance.
